CAS: 22760-18-5; 1-Isopropyl-7-Methyl-4-Phenylquinazolin-2(1H)-One

该化合物是属于非类类动物抗炎药物(NSAIDs)的化学化合物,主要因其止痛和抗炎特性而得到承认,有助于治疗疼痛和炎症; 丙功能,抑制环氧酶(COX)酶,在异丙烯酯,炎症和疼痛的调解者的生物合成中起着关键作用; 该化合物的特点是水溶性相对较低,可影响其生物利用率和体内吸收; Proquazone已经研究过其潜在的治疗作用,但也可能表现出非甲胺ID的副作用,例如胃肠不适或增加出血风险; 其药性对了解其功效和安全特征十分重要; 与任何药物一样,必须考虑个别病人因素,咨询保健专业人员,以便适当使用.

结构式图片

上下游产品

CAS号23070-81-7 2-(N-isopropyla... | CAS号598-55-0 氨基甲酸甲酯

合成工艺路线路线简述

    📜2-(N-Isopropylamino)-4-Methylbenzophenone置于尿素,苯甲酸体系中,用 甲苯 用作溶剂,化学反应生成普罗喹宗
    参考文献:Preparation Of Quinazolin-2(1H)-Ones
    标题:Preparation Of Quinazolin-2(1H)-Ones
    摘要:该发明提供了一种通过在芳香酸存在下使相应的2-氨基苯并酮与尿素或烷基氨基甲酸酯环化而生产4-苯基-2(1H)-喹唑啉酮的方法.这些产品是已知的抗炎药物.

    海关参考信息

    专利信息


    专利号:US-8546532-B2
    优先权日:2008-04-17
    标题:Synthesis of directed sequence polymer compositions and antibodies thereof for the treatment of protein conformational disorders
    发明人:BONNIN DUSTAN; ZANELLI ERIC; MATHERS THOMAS
    权利人:BONNIN DUSTAN; ZANELLI ERIC; MATHERS THOMAS; DECLION PHARMACEUTICALS INC
    摘要:The instant invention comprises a process for the solid phase synthesis of directed epitope peptide mixtures useful in the treatment and diagnosis of protein conformational disorders, such process defined by a set of rules regarding the identity and the frequency of occurrence of amino acids that substitute a base or native amino acid of a known epitope. The resulting composition is a mixture of related peptides for therapeutic use. The invention also pertains to the process of generating antibodies using the directed epitope peptide mixtures as the antigens, and antibodies generated by such process, useful in the treatment and diagnostics of the said protein conformational disorder.

    专利号:US-9051302-B2
    优先权日:2008-01-15
    标 题 :Synthesis of resorcylic acid lactones useful as therapeutic agents
    发明人:WINSSINGER NICOLAS; BARLUENGA SOFIA; KARPLUS MARTIN
    权利人:WINSSINGER NICOLAS; BARLUENGA SOFIA; KARPLUS MARTIN; UNIV STRASBOURG
    摘要:Disclosed are macrocyclic compounds of formulae I, I′, II, II′, III, III′, IV, and V, which are analogs of the pochonin resorcylic acid lactones, pharmaceutical compositions comprising the compounds, and methods and uses comprising the compounds for the treatment of diseases mediated by kinases and Heat Shock Protein 90 HSP90.

    专利号:US-2013035307-A1
    优先权日:2010-01-26
    标 题:Methods for treating or preventing the spread of cancer using semi-synthetic glycosaminoglycosan ethers
    发明人:PRESTWICH GLENN D; KENNEDY THOMAS P
    权利人:UNIV UTAH RES FOUND; PRESTWICH GLENN D; KENNEDY THOMAS P
    摘要:Described herein are methods for the treatment and prevention of tumor metastasis using alkylated and fluoroalkylated semi-synthetic glycosaminoglycan ethers (“SAGEsâ€?). The synthesis of sulfated alkylated and fluoroalkylated SAGEs is also described.

    专利号:US-2024287041-A1
    优先权日:2021-05-20
    标题 :Methods of synthesis of heteroaryl derivatives of triazolyl acrylamides and crystalline forms
    发明人:BALOGLU ERKAN; AUSTAD BRIAN C; ROE DAVID G; KEDUC ANDREW; GOTTSCHLING STEPHEN EDMUND; HECKER EVAN
    权利人:KARYOPHARM THERAPEUTICS INC
    摘要:The present invention relates to a method of preparing a compound represented by structural formula (VII), comprising reacting a compound represented by structural formula (II), with a compound represented by structural formula (III), in a solvent, in the presence of a Pd catalyst and one or more inorganic bases under conditions suitable to prepare a compound represented by structural formula (VII): The values and example values of the variables in structural formulas (VII), (II), and (III) are defined herein. The present invention also relates to crystalline Forms I and II of the compound represented by Structural Formula (VII), the use of the crystalline Forms in treating disease or disorders associated with CRM1 and method of preparing the crystalline Forms.

    专利号:WO-2023075715-A1
    优先权日:2021-10-26
    标题 :A pharmaceutical formulation including leukotriene receptor antagonists and/or leukotriene synthesis inhibitors combined with non-steroidal anti-inflammatory drugs (nsaids)
    发明人:OYTUN FARUK; CAN EFE
    权利人:VSY BIYOTEKNOLOJI VE ILAC SANAYI ANONIM SIRKETI
    摘要:This invention is related to a pharmaceutical formulation including Leukotriene receptor antagonists and/or Leukotriene synthesis inhibitors combined with non-steroidal anti-inflammatory drugs (NSAIDs) and antihistamines in ocular diseases and in inflammatory and allergic diseases for systemic and topical use. The objective of this invention is to create a novel formulation to be effective as much as steroids while having significantly less side effects for long-term use in treating ocular diseases, inflammatory and allergic diseases. In other words our aim is to achieve the inhibition of pro-inflammatory mediators (prostaglandins, thromboxane, histamine and leukotrienes) as much as steroids do with a safer combination.

    专利号:WO-2023096715-A9
    优先权日:2021-10-22
    标 题:Immunomodulatory glycosphingolipids and methods of use thereof
    发明人:KASPER DENNIS; OH SUNGWHAN
    权利人:HARVARD COLLEGE
    摘要:Provided herein are a subset of alpha-galactosylceramide (alpha-GC) compounds having improved immunomodulatory activity, particularly with respect to NKT cell number and activity. Also provided herein are methods of use of such compounds, including in the modulation of NKT cells and/or activity in vivo. Further provided are combinatorial synthesis methods for generating alpha-GC compounds of specifically defined structure and thereby generating pure preparations thereof.

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Mäkäräinen L, Ylikorkala O. Menstrual blood loss in dysmenorrhoea: effects of proquazone and indomethacin. Br J Obstet Gynaecol. 1983 Jun;90(6):570-2. German. Review.

    合成参考文献


    摘要:S72 | NTUPHTW | Pharmaceutically Active Substances from National Taiwan University | DOI:10.5281/zenodo.3955664
    参考文献:10.1080/03009748009098125|10.3109/03009748009098125
    摘要:Skrifvars B, Nissilä M. Immunological Effects of Biarison® in the Treatment of Rheumatoid Arthritis and Systemic Lupus Erythematosus: A Preliminary Report. Scandinavian Journal of Rheumatology. 1980 Jan;9(1):33–8. doi: 10.1080/03009748009098125.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知